These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38954749)

  • 1. Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator.
    Huang Y; Han Z; Shen T; Zheng Y; Yang Z; Fan J; Wang R; Yan F; Tao Z; Luo Y; Liu P
    CNS Neurosci Ther; 2024 Jul; 30(7):e14825. PubMed ID: 38954749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of NLRP3 attenuates hemorrhagic transformation after delayed rtPA treatment in thromboembolic stroke rats: Involvement of neutrophil recruitment.
    Guo Z; Yu S; Chen X; Zheng P; Hu T; Duan Z; Liu X; Liu Q; Ye R; Zhu W; Liu X
    Brain Res Bull; 2018 Mar; 137():229-240. PubMed ID: 29258866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia.
    Song HY; Chung JI; Jalin AMA; Ju C; Pahk K; Joung C; Lee S; Jin S; Kim BS; Lee KS; Ryu JM; Kim WK
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.
    Pfefferkorn T; Rosenberg GA
    Stroke; 2003 Aug; 34(8):2025-30. PubMed ID: 12855824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W; Hendren J; Qin XJ; Liu KJ
    Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
    Nakazaki M; Sasaki M; Kataoka-Sasaki Y; Oka S; Namioka T; Namioka A; Onodera R; Suzuki J; Sasaki Y; Nagahama H; Mikami T; Wanibuchi M; Kocsis JD; Honmou O
    J Neurosurg; 2017 Oct; 127(4):917-926. PubMed ID: 28059661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
    Huang L; Wang J; Huang S; Siaw-Debrah F; Nyanzu M; Zhuge Q
    Biochem Biophys Res Commun; 2019 Aug; 516(2):565-570. PubMed ID: 31235258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canonical Wnt Pathway Maintains Blood-Brain Barrier Integrity upon Ischemic Stroke and Its Activation Ameliorates Tissue Plasminogen Activator Therapy.
    Jean LeBlanc N; Menet R; Picard K; Parent G; Tremblay MÈ; ElAli A
    Mol Neurobiol; 2019 Sep; 56(9):6521-6538. PubMed ID: 30852795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
    Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
    Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?
    Haelewyn B; Risso JJ; Abraini JH
    J Cereb Blood Flow Metab; 2010 May; 30(5):900-3. PubMed ID: 20216551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator.
    Wiegler K; Bonny C; Coquoz D; Hirt L
    Cerebrovasc Dis; 2008; 26(4):360-6. PubMed ID: 18728363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.
    Gautier S; Ouk T; Tagzirt M; Lefebvre C; Laprais M; Pétrault O; Dupont A; Leys D; Bordet R
    J Neuroinflammation; 2014 May; 11():96. PubMed ID: 24885160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
    Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
    J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke.
    Huang Y; Gu S; Han Z; Yang Z; Zhong L; Li L; Wang R; Yan F; Luo Y; Borlongan C; Lu J
    J Am Heart Assoc; 2023 Sep; 12(17):e029817. PubMed ID: 37655472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
    Tanne D; Macko RF; Lin Y; Tilley BC; Levine SR;
    Stroke; 2006 Jul; 37(7):1798-804. PubMed ID: 16763191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.
    Wang W; Li M; Wang Y; Li Q; Deng G; Wan J; Yang Q; Chen Q; Wang J
    Mol Neurobiol; 2016 Dec; 53(10):7028-7036. PubMed ID: 26671619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
    You YP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):990-7. PubMed ID: 26851971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
    Shi K; Zou M; Jia DM; Shi S; Yang X; Liu Q; Dong JF; Sheth KN; Wang X; Shi FD
    Circ Res; 2021 Jan; 128(1):62-75. PubMed ID: 33070717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of connexin43 in hemorrhagic transformation after thrombolysis in vivo and in vitro.
    Yang X; Chu H; Tang Y; Dong Q
    Neuroscience; 2016 Aug; 329():54-65. PubMed ID: 27138645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
    Xu J; Wang X; Yin H; Cao X; Hu Q; Lv W; Xu Q; Gu Z; Xin H
    ACS Nano; 2019 Aug; 13(8):8577-8588. PubMed ID: 31339295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.